The Indian medical devices industry has been in focus since the pandemic. From US $ 11 billion in 2020 it is expected to touch US $ 50 billion by 2025. Mehernosh Daruwalla, Founder and MD, Lotus Surgicals shares a perspective with Thomas C Thottathil on the opportunities in this sector
GreenLight Biosciences is a Boston-based biotechnology company dedicated to making ribonucleic acid (RNA) products affordable and accessible
First-of-its-kind Incubator will support companies poised to deliver breakthrough applications in genomics and multiomics
Molnupiravir is an investigational oral antiviral medicine, for the treatment of mild-to-moderate COVID-19 in at risk adults
Strengthens supply chain continuity with first manufacturing facility outside of the U.S.
The BLA is being submitted under the accelerated approval pathway and is primarily based on clinical, biomarker and safety data from the Phase 2b clinical trial in people with early AD and confirmed amyloid pathology
Floods had forced the plans in Mahad to shut down
The product can be used by any lab that conducts NGS testing, making precision medicine accessible to all cancer patients
In addition to supporting the ongoing development of the first IND-approved product in clinical trials, the proceeds will also be used to expand the 3D printed drug product pipeline
Revenues from operations for FY21 stood at Rs. 202.38 crore as compared to 167.27 crore, up by 21%
Subscribe To Our Newsletter & Stay Updated
